An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Trial Profile

An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Kura Oncology
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 According to a Kura Oncology media release, data expected during the first half of 2018.
    • 14 Mar 2017 According to a Kura Oncology media release, based on anecdotal evidence of hematological improvement observed in several patients,company has amended the study to evaluate further dose regimens to optimize those initial findings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top